Search Back New search Go to resultsDiseaseMain groupHematological Diseases, Non-MalignantProtocol groupAnemias, CytopeniasDiseaseThrombotic Thrombocytopenic PurpuraSubgroupICD10M31.1MeSHPurpura, Thrombotic ThrombocytopenicSequenceCAPL10, TTP, C1 (PID2111) -|- C2+ (PID2112)ChemotherapyChemo-substanceChemo-substanceChemo-substanceChemo-substanceNo. Substances RadiotherapySupportive therapySupportive substanceCaplacizumabSupportive substanceCaplacizumabSupportive substanceCaplacizumabSupportive substanceCaplacizumabNo. Substances1Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationTherapy phaseTherapy intentiondisease controlRisksBleedingDyspneaHeadacheRash only studiesPublicationAuthorScully MDiseaseTTP, älter 18 JahreOriginClinical Development, Ablynx, Zwijnaarde, Belgium, HERCULES investigatorsProtocols in Revision 2 protocols foundProtocols under revision.Caplacizumab 10, Thrombotic Thrombocytopenic Purpura, cycle 1 (PID2111 V1.0)Caplacizumab 10, Thrombotic Thrombocytopenic Purpura, cycle 2+ (PID2112 V1.0)
